Ensuring the quality of stem cell-derived in vitro models for toxicity testing

Glyn N. Stacey; Sandra Coecke; Anna Bal Price; Lyn Healy; Paul Jennings; Anja Wilmes; Christian Pinset; Magnus Ingelman-Sundberg; Jochem Louisse; Simone Haupt; Darren Kidd; Andrea Robitski; Heinz Georg Jahnke; Gilles Lemaitre; Glenn Myatt

doi:10.1007/978-3-319-33826-2_11

Ensuring the quality of stem cell-derived in vitro models for toxicity testing

Glyn N. Stacey^*, Sandra Coecke, Anna Bal Price, Lyn Healy, Paul Jennings, Anja Wilmes, Christian Pinset, Magnus Ingelman-Sundberg, Jochem Louisse, Simone Haupt, Darren Kidd, Andrea Robitski, Heinz Georg Jahnke, Gilles Lemaitre, Glenn Myatt

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

7 Citations (Scopus)

Abstract

Quality control of cell cultures used in new in vitro toxicology assays is crucial to the provision of reliable, reproducible and accurate toxicity data on new drugs or constituents of new consumer products. This chapter explores the key scientific and ethical criteria that must be addressed at the earliest stages of developing toxicology assays based on human pluripotent stem cell (hPSC) lines. It also identifies key considerations for such assays to be acceptable for regulatory, laboratory safety and commercial purposes. Also addressed is the development of hPSC-based assays for the tissue and cell types of greatest interest in drug toxicology. The chapter draws on a range of expert opinion within the European Commission/Cosmetics Europe-funded alternative testing cluster SEURAT-1 and consensus from international groups delivering this guidance such as the International Stem Cell Banking Initiative. Accordingly, the chapter summarizes the most up-date best practices in the use and quality control of human Pluripotent Stem Cell lines in the development of in vitro toxicity assays from leading experts in the field.

Original language	English
Title of host publication	Validation of Alternative Methods for Toxicity Testing
Editors	C. Eskes, M. Whelan
Place of Publication	Cham
Publisher	Springer New York LLC
Pages	259-297
Number of pages	39
ISBN (Electronic)	9783319338262
ISBN (Print)	9783319338248
DOIs	https://doi.org/10.1007/978-3-319-33826-2_11
Publication status	Published - 27 Sep 2016

Publication series

Name	Advances in Experimental Medicine and Biology
Volume	856
ISSN (Print)	0065-2598
ISSN (Electronic)	2214-8019

Keywords

Quality control
Stem cell characterisation
Stem cell differentiation
Toxicology

Access to Document

10.1007/978-3-319-33826-2_11

Cite this

Stacey, G. N., Coecke, S., Price, A. B., Healy, L., Jennings, P., Wilmes, A., Pinset, C., Ingelman-Sundberg, M., Louisse, J., Haupt, S., Kidd, D., Robitski, A., Jahnke, H. G., Lemaitre, G., & Myatt, G. (2016). Ensuring the quality of stem cell-derived in vitro models for toxicity testing. In C. Eskes, & M. Whelan (Eds.), Validation of Alternative Methods for Toxicity Testing (pp. 259-297). (Advances in Experimental Medicine and Biology; Vol. 856). Springer New York LLC. https://doi.org/10.1007/978-3-319-33826-2_11

@inbook{697e7f82066842d687717992b7e832c2,

title = "Ensuring the quality of stem cell-derived in vitro models for toxicity testing",

abstract = "Quality control of cell cultures used in new in vitro toxicology assays is crucial to the provision of reliable, reproducible and accurate toxicity data on new drugs or constituents of new consumer products. This chapter explores the key scientific and ethical criteria that must be addressed at the earliest stages of developing toxicology assays based on human pluripotent stem cell (hPSC) lines. It also identifies key considerations for such assays to be acceptable for regulatory, laboratory safety and commercial purposes. Also addressed is the development of hPSC-based assays for the tissue and cell types of greatest interest in drug toxicology. The chapter draws on a range of expert opinion within the European Commission/Cosmetics Europe-funded alternative testing cluster SEURAT-1 and consensus from international groups delivering this guidance such as the International Stem Cell Banking Initiative. Accordingly, the chapter summarizes the most up-date best practices in the use and quality control of human Pluripotent Stem Cell lines in the development of in vitro toxicity assays from leading experts in the field.",

keywords = "Quality control, Stem cell characterisation, Stem cell differentiation, Toxicology",

author = "Stacey, {Glyn N.} and Sandra Coecke and Price, {Anna Bal} and Lyn Healy and Paul Jennings and Anja Wilmes and Christian Pinset and Magnus Ingelman-Sundberg and Jochem Louisse and Simone Haupt and Darren Kidd and Andrea Robitski and Jahnke, {Heinz Georg} and Gilles Lemaitre and Glenn Myatt",

year = "2016",

month = sep,

day = "27",

doi = "10.1007/978-3-319-33826-2_11",

language = "English",

isbn = "9783319338248",

series = "Advances in Experimental Medicine and Biology",

publisher = "Springer New York LLC",

pages = "259--297",

editor = "C. Eskes and M. Whelan",

booktitle = "Validation of Alternative Methods for Toxicity Testing",

}

Stacey, GN, Coecke, S, Price, AB, Healy, L, Jennings, P, Wilmes, A, Pinset, C, Ingelman-Sundberg, M, Louisse, J, Haupt, S, Kidd, D, Robitski, A, Jahnke, HG, Lemaitre, G & Myatt, G 2016, Ensuring the quality of stem cell-derived in vitro models for toxicity testing. in C Eskes & M Whelan (eds), Validation of Alternative Methods for Toxicity Testing. Advances in Experimental Medicine and Biology, vol. 856, Springer New York LLC, Cham, pp. 259-297. https://doi.org/10.1007/978-3-319-33826-2_11

Ensuring the quality of stem cell-derived in vitro models for toxicity testing. / Stacey, Glyn N.; Coecke, Sandra; Price, Anna Bal et al.

Validation of Alternative Methods for Toxicity Testing. ed. / C. Eskes; M. Whelan. Cham : Springer New York LLC, 2016. p. 259-297 (Advances in Experimental Medicine and Biology; Vol. 856).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

TY - CHAP

T1 - Ensuring the quality of stem cell-derived in vitro models for toxicity testing

AU - Stacey, Glyn N.

AU - Coecke, Sandra

AU - Price, Anna Bal

AU - Healy, Lyn

AU - Jennings, Paul

AU - Wilmes, Anja

AU - Pinset, Christian

AU - Ingelman-Sundberg, Magnus

AU - Louisse, Jochem

AU - Haupt, Simone

AU - Kidd, Darren

AU - Robitski, Andrea

AU - Jahnke, Heinz Georg

AU - Lemaitre, Gilles

AU - Myatt, Glenn

PY - 2016/9/27

Y1 - 2016/9/27

N2 - Quality control of cell cultures used in new in vitro toxicology assays is crucial to the provision of reliable, reproducible and accurate toxicity data on new drugs or constituents of new consumer products. This chapter explores the key scientific and ethical criteria that must be addressed at the earliest stages of developing toxicology assays based on human pluripotent stem cell (hPSC) lines. It also identifies key considerations for such assays to be acceptable for regulatory, laboratory safety and commercial purposes. Also addressed is the development of hPSC-based assays for the tissue and cell types of greatest interest in drug toxicology. The chapter draws on a range of expert opinion within the European Commission/Cosmetics Europe-funded alternative testing cluster SEURAT-1 and consensus from international groups delivering this guidance such as the International Stem Cell Banking Initiative. Accordingly, the chapter summarizes the most up-date best practices in the use and quality control of human Pluripotent Stem Cell lines in the development of in vitro toxicity assays from leading experts in the field.

AB - Quality control of cell cultures used in new in vitro toxicology assays is crucial to the provision of reliable, reproducible and accurate toxicity data on new drugs or constituents of new consumer products. This chapter explores the key scientific and ethical criteria that must be addressed at the earliest stages of developing toxicology assays based on human pluripotent stem cell (hPSC) lines. It also identifies key considerations for such assays to be acceptable for regulatory, laboratory safety and commercial purposes. Also addressed is the development of hPSC-based assays for the tissue and cell types of greatest interest in drug toxicology. The chapter draws on a range of expert opinion within the European Commission/Cosmetics Europe-funded alternative testing cluster SEURAT-1 and consensus from international groups delivering this guidance such as the International Stem Cell Banking Initiative. Accordingly, the chapter summarizes the most up-date best practices in the use and quality control of human Pluripotent Stem Cell lines in the development of in vitro toxicity assays from leading experts in the field.

KW - Quality control

KW - Stem cell characterisation

KW - Stem cell differentiation

KW - Toxicology

U2 - 10.1007/978-3-319-33826-2_11

DO - 10.1007/978-3-319-33826-2_11

M3 - Chapter

C2 - 27671727

AN - SCOPUS:84988983526

SN - 9783319338248

T3 - Advances in Experimental Medicine and Biology

SP - 259

EP - 297

BT - Validation of Alternative Methods for Toxicity Testing

A2 - Eskes, C.

A2 - Whelan, M.

PB - Springer New York LLC

CY - Cham

ER -

Ensuring the quality of stem cell-derived in vitro models for toxicity testing

Abstract

Publication series

Keywords

Access to Document

Fingerprint

Cite this